{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:57:43Z","timestamp":1787061463882,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Renal allograft rejection is more frequent under belatacept-based, compared with tacrolimus-based, immunosuppression. We studied kidney transplant recipients experiencing rejection under belatacept-based early corticosteroid withdrawal following T-cell\u2013depleting induction in a recent randomized trial (Belatacept-based Early Steroid Withdrawal Trial, clinicaltrials.gov NCT01729494) to determine mechanisms of rejection and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      Peripheral mononuclear cells, serum creatinine levels, and renal biopsies were collected from 8 patients undergoing belatacept-refractory rejection (BRR). We used flow cytometry, histology, and immunofluorescence to characterize CD8\n                      <jats:sup>+<\/jats:sup>\n                      effector memory T cell (T\n                      <jats:sub>EM<\/jats:sub>\n                      ) populations in the periphery and graft before and after mammalian target of rapamycin (mTOR) inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Here, we found that patients with BRR did not respond to standard antirejection therapy and had a substantial increase in alloreactive CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells with a CD28\n                      <jats:sup>low<\/jats:sup>\n                      \/DR\n                      <jats:sup>hi<\/jats:sup>\n                      \/CD38\n                      <jats:sup>hi<\/jats:sup>\n                      \/CD45RO\n                      <jats:sup>+<\/jats:sup>\n                      T\n                      <jats:sub>EM<\/jats:sub>\n                      . These cells had increased activation of the mTOR pathway, as assessed by phosphorylated ribosomal protein S6 expression. Notably, everolimus (an mTOR inhibitor) treatment of patients with BRR halted the in vivo proliferation of T\n                      <jats:sub>EM<\/jats:sub>\n                      cells and their ex vivo alloreactivity and resulted in their significant reduction in the peripheral blood. The frequency of circulating FoxP3\n                      <jats:sup>+<\/jats:sup>\n                      regulatory T cells was not altered. Importantly, everolimus led to rapid resolution of rejection as confirmed by histology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Thus, while prior work has shown that concomitant belatacept\u2009+\u2009mTOR inhibitor therapy is effective for maintenance immunosuppression, our preliminary data suggest that everolimus may provide an available means for effecting \u201crescue\u201d therapy for rejections occurring under belatacept that are refractory to traditional antirejection therapy with corticosteroids and polyclonal antilymphocyte globulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000002917","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T07:33:41Z","timestamp":1565768021000},"page":"1058-1069","source":"Crossref","is-referenced-by-count":23,"title":["mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28\u2212 Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection"],"prefix":"10.1097","volume":"104","author":[{"given":"Cyd M.","family":"Castro-Rojas","sequence":"first","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzbeta","family":"Godarova","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Hummel","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Shields","sequence":"additional","affiliation":[{"name":"Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita R.","family":"Alloway","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Research Foundation, Cincinnati, OH."},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Steve","family":"Woodle","sequence":"additional","affiliation":[{"name":"Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hildeman","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH."},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/tri.12605","article-title":"Does belatacept improve outcomes for kidney transplant recipients? A systematic review.","volume":"28","author":"Talawila","year":"2015","journal-title":"Transpl Int"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1056\/NEJMe1515765","article-title":"The clearer BENEFITS of belatacept.","volume":"374","author":"Heher","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation.","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1097\/TP.0000000000001755","article-title":"A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation.","volume":"101","author":"de Graav","year":"2017","journal-title":"Transplantation"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1111\/ajt.14377","article-title":"Lessons learned: early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using belatacept.","volume":"17","author":"Newell","year":"2017","journal-title":"Am J Transplant"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ajt.12574","article-title":"The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.","volume":"14","author":"Xu","year":"2014","journal-title":"Am J Transplant"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"e0148604","DOI":"10.1371\/journal.pone.0148604","article-title":"Down-regulation of surface CD28 under belatacept treatment: an escape mechanism for antigen-reactive T-cells.","volume":"11","author":"de Graav","year":"2016","journal-title":"PLOS One"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells.","volume":"17","author":"Mathews","year":"2017","journal-title":"Am J Transplant"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-6143.2010.03317.x","article-title":"Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.","volume":"11","author":"Lo","year":"2011","journal-title":"Am J Transplant"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nm.1993","article-title":"Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.","volume":"15","author":"Weaver","year":"2009","journal-title":"Nat Med"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1172\/JCI77746","article-title":"mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation.","volume":"125","author":"Pollizzi","year":"2015","journal-title":"J Clin Invest"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/00007890-199610150-00006","article-title":"Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies.","volume":"62","author":"Woodle","year":"1996","journal-title":"Transplantation"},{"key":"R18-20231002","article-title":"A protocol for single-cell transcriptomics from cryopreserved renal tissue and urine for the Accelerating Medicine Partnership (AMP) RA\/SLE network.","author":"Deepak","year":"2018","journal-title":"bioRxiv"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/01.tp.0000241077.83511.be","article-title":"Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants.","volume":"82","author":"Jones","year":"2006","journal-title":"Transplantation"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-6143.2012.04342.x","article-title":"Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.","volume":"13","author":"Lo","year":"2013","journal-title":"Am J Transplant"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/imm.12603","article-title":"Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.","volume":"148","author":"Merino","year":"2016","journal-title":"Immunology"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fmed.2017.00060","article-title":"Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants.","volume":"4","author":"Kumar","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/14712590902942284","article-title":"Costimulatory blockade with belatacept in clinical and experimental transplantation - a review.","volume":"9","author":"Emamaullee","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/TP.0000000000001004","article-title":"An acute cellular rejection with detrimental outcome occurring under belatacept-based immunosuppressive therapy: an immunological analysis.","volume":"100","author":"de Graav","year":"2016","journal-title":"Transplantation"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/ajt.12937","article-title":"CD28 negative T cells: is their loss our gain?","volume":"14","author":"Mou","year":"2014","journal-title":"Am J Transplant"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2007.02078.x","article-title":"Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.","volume":"8","author":"Trzonkowski","year":"2008","journal-title":"Am J Transplant"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection.","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am J Transplant"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ajt.12669","article-title":"Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.","volume":"14","author":"Jin","year":"2014","journal-title":"Am J Transplant"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.180.4.2357","article-title":"HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway.","volume":"180","author":"Jindra","year":"2008","journal-title":"J Immunol"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"e0156535","DOI":"10.1371\/journal.pone.0156535","article-title":"Immunoregulatory effects of everolimus on in vitro alloimmune responses.","volume":"11","author":"Levitsky","year":"2016","journal-title":"PLOS One"},{"key":"R32-20231002","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/TP.0000000000000717","article-title":"Differential effects of calcineurin and mammalian target of rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells.","volume":"99","author":"Gallon","year":"2015","journal-title":"Transplantation"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1172\/JCI90598","article-title":"Transplant trials with Tregs: perils and promises.","volume":"127","author":"Tang","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T01:22:37Z","timestamp":1696209757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002917","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}